Sevilla, Octubre de 2012.- La Sociedad Española de Cardiología (SEC) acaba de presentar en el marco de la XLVIII edición del Congreso de las Enfermedades Cardiovasculares SEC 2012, la realización de un estudio pionero en nuestro país que determinará el riesgo de eventos tromboembólicos y hemorrágicos así como la relación coste-efectividad de los nuevos anticoagulantes administrados a pacientes con fibrilación auricular no valvular (FA).
St. Jude Medical Inc. (STJ) s device to plug openings in the heart after a stroke failed to definitively prevent repeat incidents in patients under age 60 compared with non-surgical drug treatment, two studies found.
Second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions, according to results of the ISAR-LEFT MAIN 2 trial presented at the TCT congress on 24 October. Data from the study were presented by lead investigator, Julinda Mehilli, director of Catheterization Laboratories at the Medizinische Klinik I, Klinikum der Universitaet Munich, Munich, Germany.
A new analysis of the global RESOLUTE clinical trial has shown that interrupting dual antiplatelet therapy after 30 days following the implantation of a Resolute drug-eluting stent (Medtronic) caused no increase in rates of stent thrombosis at one year. The analysis was presented by Sigmund Silber, director of the Heart Centre at the Isar in Munich, Germany, at TCT.
Stentys has received investigational device exemption (IDE) approval from the FDA to conduct a pivotal clinical trial in the United States which, if successfully completed, will enable the company to apply for marketing approval of the Stentys Self-Apposing stent to treat acute myocardial infarction.
Volcano has announced the global launch of the PrimeWire Prestige Plus pressure guidewire with AcuSense technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time.
Results from the DISCOVER CE mark trial have shown that the Direct Flow Medical Transcatheter Aortic Valve System met its primary mortality endpoint. The study also demonstrated that greater than 95% of patients had mild or less aortic regurgitation, and no patients experienced vascular complications. Data were presented by co-principal investigator Joachim Schofer, Medical Care Center, Hamburg, Germany, at the TCT congress.
Five-year results from the LEADERS trial have shown improved long-term clinical outcomes for BioMatrix Flex Biolimus A9-eluting stent system (Biosensors) compared to Cypher Select sirolimus-eluting stent system (Johnson & Johnson). BioMatrix Flex significantly reduced the risk of clinical events compared with Cypher Select, which was associated with a reduced risk of very late stent thrombosis (VLST).
CardioKinetix has received CE mark approval for the full size matrix of its Parachute Ventricular Partitioning Device for percutaneous ventricular restoration (PVR) therapy.
Micro Interventional Devices has announced that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal. The patient is the first to be enrolled in the company’s European STASIS clinical trial.
For two decades, doctors have used a dime-sized plug made by St. Jude Medical Inc. to close holes found in the hearts of stroke victims in a surgery that’s based largely on a medical theory.
SAN DIEGO, Oct. 23, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced the global launch of the PrimeWire Prestige® PLUS pressure guide wire with AcuSense technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time. The new offering is the fourth new pressure guide wire from Volcano in four years and will serve as the platform for Volcano s expanding clinical programs. The PrimeWire Prestige PLUS product will be used in six newly announced Volcano-sponsored clinical studies to explore new indications in stable and unstable CAD, peripheral arterial disease and neurology.
At TCT, Paul S Teirstein, Scripps Clinic in La Jolla, California, presented clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the Promus Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System (Boston Scientific) in patients with long coronary lesions.
The US Food and Drug Administration (FDA) has approved the use of the new Gore septal occluder for inclusion in the Gore REDUCE clinical study. Gore is introducing the technology in the REDUCE study for prevention of recurrent stroke in patent foramen ovale (PFO) patients.
The ADVANCE study findings were presented this week at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 (Miami, USA, 22–27 October). Initial one year results of the study revealed that patients experienced high survival rates, with one year survival at 82.1% and one year cardiovascular survival at 88.2% Health-related quality of life (HRQoL) measured for patients in the study had improved significantly at one and six months, compared with their status prior to receiving the Medtronic CoreValve System. The study represents the largest, most rigorously collected evaluation of HRQoL findings published on transcatheter aortic valve implantation (TAVI). The CoreValve System is currently limited to investigational use in the United States.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos